Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh
View: Text | PDF
Research Article Inflammation Oncology

Human-specific elimination of epithelial Siglec-XII suppresses the risk of inflammation-driven colorectal cancers

  • Text
  • PDF
Abstract

Carcinomas are common in humans but rare among closely related “great apes.” Plausible explanations, including human-specific genomic alterations affecting the biology of sialic acids, are proposed, but causality remains unproven. Here, an integrated evolutionary genetics-phenome-transcriptome approach studied the role of SIGLEC12 gene (encoding Siglec-XII) in epithelial transformation and cancer. Exogenous expression of the protein in cell lines and genetically engineered mice recapitulated approximately 30% of the human population in whom the protein is expressed in a form that cannot bind ligand because of a fixed, homozygous, human-universal missense mutation. Siglec-XII–null cells/mice recapitulated the remaining approximately 70% of the human population in whom an additional polymorphic frameshift mutation eliminates the entire protein. Siglec-XII expression drove several pro-oncogenic phenotypes in cell lines and increased tumor burden in mice challenged with chemical carcinogen and inflammation. Transcriptomic studies yielded a 29-gene signature of Siglec-XII–positive disease and when used as a computational tool for navigating human data sets, pinpointed with surprising precision that SIGLEC12 expression (model) recapitulates a very specific type of colorectal carcinomas (disease) that is associated with mismatch-repair defects and inflammation, disproportionately affects European Americans, and carries a favorable prognosis. They revealed a hitherto-unknown evolutionary genetic mechanism for an ethnic/environmental predisposition of carcinogenesis.

Authors

Hector A. Cuello, Saptarshi Sinha, Andrea L. Verhagen, Nissi Varki, Ajit Varki, Pradipta Ghosh

×

Figure 2

Forced expression of Siglec-XII in null human carcinoma cell lines enhances cellular processes associated with tumor aggressiveness.

Options: View larger image (or click on image) Download as PowerPoint
Forced expression of Siglec-XII in null human carcinoma cell lines enhan...
(A and B) Graphs display cell adhesion on a 2D surface for PC-3 (A) and Caco-2 (B) cells, as measured by crystal violet staining. (C–E) Graphs (C, PC-3; D, Caco-2) display cellular viability of the same cells in 3D tumoroid cultures. Representative images are displayed (E). Scale bar: 100 μm. (F and G) Graphs display percentage migration of PC-3 (F) and Caco-2 (G) cells, as determined by Transwell assays (0%–10% serum gradient). (H–K) Quantitative immunoblotting on equal aliquots of whole cell lysates of PC-3 (H and I) or Caco-2 (J and K) cells to assess ERK1/2 activity. Blots results were set up in parallel, run contemporaneously, and normalized to loading controls (β-Actin). OD, optical density. Representative immunoblots are shown in H and J, and quantification of 3 independent repeats is shown as bar graphs in I and K. Error bars indicate ± SD. See also Supplemental Figure 1 for approaches used to verify the Siglec-XII–null state. Statistics: P values were calculated using GraphPad Prism. P < 0.05 was considered significant. A–D, ANOVA followed by Tukey’s multiple comparisons post hoc test. F, G, and K, 2-tailed t test. I, 1-tailed t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts